Department of Dermatology, Venereology & Allergology, Medical University, Wroclaw, Poland.
Immunotherapy. 2019 Jan;11(1):45-59. doi: 10.2217/imt-2018-0090.
Hidradenitis suppurativa (HS) is a chronic, inflammatory dermatosis characterized by an occurrence of nodules, abscesses, sinus tracks and scarring. Its pathogenesis is multifactorial and still not fully understood, therefore, current systemic therapies still remain a serious challenge. Increased levels of several proinflammatory cytokines have been reported in patients suffering from HS, therefore biologics appear as a new approach to therapy for this condition. Adalimumab is the only one internationally registered agent and should be considered first after the conventional therapies appear insufficient. The efficacy and safety profile of some preparations, like infliximab and etanercept was confirmed so far in randomized trials, but there are some new biologics which are still being evaluated and require more rigorous examination.
化脓性汗腺炎（HS）是一种慢性炎症性皮肤病，其特征为结节、脓肿、窦道和瘢痕的发生。其发病机制是多因素的，仍不完全清楚，因此，目前的全身治疗仍然是一个严重的挑战。患有 HS 的患者的几种促炎细胞因子水平升高，因此生物制剂似乎是治疗这种疾病的新方法。阿达木单抗是唯一一种国际注册药物，在常规治疗效果不佳时应首先考虑。迄今为止，一些制剂（如英夫利昔单抗和依那西普）的疗效和安全性已在随机试验中得到证实，但还有一些新的生物制剂仍在评估中，需要更严格的检查。
